Symbol="INAB"
AssetType="Common Stock"
Name="In8bioÂ Inc"
Description="IN8bio, Inc., a clinical-stage biotechnology company, is focused on developing new therapies for the treatment of cancers, including solid tumors using genetically modified, autologous, allogeneic gamma-delta T cells. The company is headquartered in New York, New York."
CIK="1740279"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="EMPIRE STATE BUILDING, 350 5TH AVENUE, SUITE 5330, NEW YORK, NY, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="38377900"
EBITDA="-29357000"
PERatio="None"
PEGRatio="None"
BookValue="0.673"
DividendPerShare="0"
DividendYield="0"
EPS="-1.15"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.617"
ReturnOnEquityTTM="-1.205"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-1.15"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="11.33"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="1.956"
EVToRevenue="-"
EVToEBITDA="-1.368"
Beta="None"
num_52WeekHigh="3.95"
num_52WeekLow="1.02"
num_50DayMovingAverage="2.082"
num_200DayMovingAverage="1.898"
SharesOutstanding="29750300"
DividendDate="None"
ExDividendDate="None"
symbol="INAB"
open="1.27"
high="1.34"
low="1.26"
price="1.29"
volume="83529.00"
latest_trading_day="2023-07-28"
previous_close="1.25"
change="0.04"
change_percent="3.6145%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="36"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="64"
Volume_recent_avg="2427229"
Change_recent_avg="-0.02"
Delta_recent_avg="0.22"
Variance_recent_avg="0.11"
Change_ratio_recent_avg="-1.6"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="64"
Aroon_momentum_negative="36"
image_negative_thumbnail_id_1="1141"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0174.jpeg"
image_negative_thumbnail_id_2="1145"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0178.jpeg"
image_neutral_thumbnail_id_1="571"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0028.jpeg"
image_neutral_thumbnail_id_2="578"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0021.jpeg"
image_positive_thumbnail_id_1="959"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0121.jpeg"
image_positive_thumbnail_id_2="981"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0143.jpeg"
image_professor_thumbnail_id_1="1200"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0034.jpeg"
image_professor_thumbnail_id_2="1199"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0033.jpeg"
